Nervous Disorder TRIZ Cases

DOS cyclic peptides inhibit sestrin-MAPK complexes, resolving the contradiction between effective immune rejuvenation and complex multi-week treatment regimens.

Antibodies targeting PrP residues 131 to 153 disrupt Aβ binding, addressing toxicity and synaptic plasticity impairments in Alzheimer's disease.

A boron-dipyrrin complex catalyzes targeted amyloid oxidation while maintaining stability under light irradiation.

Segmented antibody fragments resolve the contradiction between achieving specific NEDP1 inhibition and managing therapeutic agent complexity.

Lockable containers with weight sensors track medication consumption to prevent opioid misuse.

Monoclonal antibodies target myostatin to prevent cross-reactivity with GDF11, increasing muscle mass and improving glucose homeostasis.

Modulating wildtype or variant piRNA levels corrects aberrant expression patterns to treat cancer while reducing side effects from conventional therapies.

Peptides prevent CRMP2-SUMOylation to modulate Nav1.7 trafficking, reducing nociception without opioid side effects.

Oral C5 ketone bodies fuel the TCA cycle via acetyl-CoA conversion, improving metabolic control without strict dietary restrictions.

UBA5 inhibitors block flavivirus replication by targeting host enzyme function.

An antibody-based molecule administered to the mother transfers via the placenta to stimulate fetal MuSK kinase activity.

Transfected fibroblasts secrete progranulin to inhibit apoptosis and reduce inflammation associated with frontotemporal dementia progression.

Enhancing TIMP2 activity inhibits matrix metalloproteinases to reverse aging-associated cognitive impairment.

Engineered stem cells constitutively express indoleamine 2,3-dioxygenase to generate immunosuppressive kynurenine.

Segmenting antibody structures into intermediary polypeptides enhances targeted cell clearance while reducing adverse effects from full antibody therapies.

Soaking neural cell aggregates in cryopreservation solution before freezing prevents dehydration injury and maintains functional properties.

Calculating washout duration based on elimination half-life reduces serotonin syndrome risk in obese patients with reduced CYP2D6 function.

Antibody formulations targeting human amyloid A peptide reverse peripheral neuropathy in AL amyloidosis patients.

Cyclic amino acid modifications prevent proteolytic degradation, extending the in vivo half-life of modified GIP analogues from two minutes to several hours.

Humanized anti-TDP-43 antibodies resolve the lack of specific diagnostic tools by binding misfolded proteins to quantify pathology in ALS and FTD patients.

Engineering rAAV capsids with specific amino acid substitutions improves transduction efficiency in target tissues while reducing off-target effects.

Group II metabotropic glutamate receptor modulators rescue behavioral deficits by correcting reduced rebound bursting in the thalamic reticular nucleus.

Periodate oxidation generates aldehyde groups on avidin to form covalent bonds with tissue proteins.

Pimavanserin selectively blocks serotonin receptors to treat psychosis without impairing cognitive function or causing motor side effects.

A pharmaceutical composition combining five plant extracts to inhibit inflammatory responses and reduce C-Reactive protein levels.

Compressed GHB tablet uses surfactant excipients to overcome hygroscopicity and achieve bioequivalence with oral solutions.

Sceptridium ternatum extract protects brain nerve cells from ischemic damage through antioxidant and calcium channel blocking mechanisms.

Introducing A:A mismatches in the guide strand reduces off-target binding while preserving normal protein levels.

Segmenting alpha-synuclein into specific epitopes induces targeted immunogenic responses that reduce Lewy body inclusions.

MEK inhibitors target Ras-Erk activation to restore synaptic plasticity while minimizing off-target kinase effects.

Carbohydrate-functionalized nanoparticles transport therapeutic agents across the blood-brain barrier, overcoming tight junctions that block over 95% of drugs.

Tapered dosing reduces adverse events while maintaining treatment effectiveness.

Optimized lipid fractions in a ketogenic infant formula resolve the trade-off between seizure control and growth retardation.

Targeted mutations in beta-glucocerebrosidase improve thermal stability and lysosomal targeting, resolving low bioactivity in enzyme replacement therapies.

A recombinant diphtheria toxin platform delivers diverse polypeptide cargo into mammalian cells via specific receptor binding and translocation.

Optimized low-THC cannabis formulation combined with herbal extracts and vitamins alleviates fatigue while minimizing adverse effects.

Engineered ganglioside binding moieties fuse to clostridial light chains, resolving the trade-off between broad activity and specificity to reduce side effects.

Humanized anti-PHF-tau antibodies selectively bind pathogenic phospho-tau seeds, preventing tauopathy spreading without interfering with normal tau function.

Aldehyde compounds inhibit 2019-nCoV 3CL protease, blocking viral replication while balancing efficacy against toxicity concerns.

Sodium meta arsenite reduces pain and inflammation through targeted modulation of inflammatory mediators.

Mixed disulfide conjugates bypass P450 bioactivation to deliver rapid antiplatelet onset and consistent dosing without toxic reactive byproducts.

Segmenting active zone machinery via fusion proteins resolves complexity trade-offs to enhance neurotransmitter secretion.

Incorporating fibrinogen, thrombin, and CaCl2 into a non-permeable polymer film eliminates mesh components while ensuring reliable hemostatic sealing.

An agonist anti-TREM2 antibody reduces intracellular lipid accumulation in myeloid cells, addressing inadequate treatments for dysregulated lipid metabolism.

Soaking medicinal materials in a calcium ion and alcohol mixture improves transdermal absorption rates, bypassing digestive tract irritation.

Specific light chain mutations prevent dendritic cell maturation while depleting pathogenic T cells.

Linking glucagon superfamily peptides to NMDA antagonists reverses neuronal degeneration beyond symptomatic relief.